Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 74Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Non-Hodgkin 54Glioblastoma 41Lymphoma, Mantle-Cell 40Lymphoma, Follicular 37Hodgkin Disease 36Central Nervous System Neoplasms 32Gliosarcoma 29Brain Neoplasms 28Astrocytoma 28Lymphoma, Large-Cell, Immunoblastic 26Burkitt Lymphoma 25Multiple Myeloma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Glioma 20Oligodendroglioma 16Lymphoma, B-Cell, Marginal Zone 15Neoplasms, Plasma Cell 14Leukemia 13Recurrence 10Lymphoma, B-Cell 9Lymphoma, T-Cell 8Waldenstrom Macroglobulinemia 6Lymphoma, T-Cell, Cutaneous 6Leukemia, Myeloid, Acute 6Ependymoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5

Interventions

Melphalan 3Blood Specimen Collection 3Magnetic Resonance Spectroscopy 2thymoglobulin 1sargramostim 1romidepsin 1montanide ISA 51 1keyhole-limpet hemocyanin 1ixazomib 1detox adjuvant 1Waiting Lists 1Ursodeoxycholic Acid 1Transplantation 1Thalidomide 1Tablets 1Streptozocin 1Radiosurgery 1Radiation 1Mercaptopurine 1Leucovorin 1Ketoconazole 1Interleukin-2 1Fulvestrant 1Floxuridine 1FANG vaccine 1Docetaxel 1Cord Blood Stem Cell Transplantation 1Clinical Trials, Phase II as Topic 1Circulating Tumor DNA 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Genetic Diseases, Inborn × Carmustine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡